The Global Immuno-Oncology Therapy Market: Present and Future (2015-2020)
RCubes Research and Consulting conducts deep dive market research on emerging technologies in the healthcare and life sciences industry.
The Global Immuno-Oncology Therapy Market: Present and Future (2015-2020), covers the oncology therapy market landscape, the prevalence of the main cancer types, the cost of treatment of key approved drugs, and the regulatory pathway. The report also provides information on the various drugs in different stages of development, profiles of companies that are on track to emerge as dominant players in this market. The report also provides expert commentary on the future of the market, on the strategies that will be successful in maintaining a leading position in this market.
RCubes estimates the oncology therapy market will be $150 Billion by 2020 mainly driven by the legacy brands Rituxan & Avastin and by the immuno-oncology brands Revelimid, Opdivo, Keytruda, Xtandi etc.
Key Findings
The report will enable you to
The Global Immuno-Oncology Therapy Market: Present and Future (2015-2020), covers the oncology therapy market landscape, the prevalence of the main cancer types, the cost of treatment of key approved drugs, and the regulatory pathway. The report also provides information on the various drugs in different stages of development, profiles of companies that are on track to emerge as dominant players in this market. The report also provides expert commentary on the future of the market, on the strategies that will be successful in maintaining a leading position in this market.
RCubes estimates the oncology therapy market will be $150 Billion by 2020 mainly driven by the legacy brands Rituxan & Avastin and by the immuno-oncology brands Revelimid, Opdivo, Keytruda, Xtandi etc.
Key Findings
- Combination drugs prove to be more efficient and Companies will strive to develop/partner drugs which can form an effective combination with their existing/upcoming drugs.
- Roche will emerge as a dominant player due to its strong legacy brands, impressive immuno-oncology portfolio and strong pipeline combined with its expertise in biotechnology.
- BMS and Merck will compete with Opdivo and Keytruda respectively for approvals as first line treatment for multiple indications.
- Partnerships/Alliances will be rampant as pharmaceutical companies look out for opportunities in Immuno-Oncology that biotech companies will present.
The report will enable you to
- Understand the Oncology therapy market - the emergence of Immuno-Oncology and its success in controlling disease progression & patient survival rates.
- Develop a business strategy by understanding the prevalence of different types of cancers, the standard of care and the unmet need.
- Develop a pricing and market access strategy by understanding the cost of treatment for drugs that are launched recently, the challenges posed by reimbursement watch dogs, and to understand what companies are doing to obtain a favorable pricing.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify and research opportunities in markets where there are unmet needs to fuel future growth.
- Establish and maintain competitive information that delivers actionable insights to drive growth to core products and influence key product and marketing decisions.
- Formulate business strategy by identifying growth pockets in the Oncology market and develop in-licensing/out-licensing and partnerships/acquisitions with established/emerging companies in this space.
- Organize your R&D efforts by analyzing your competitor’s development plan, current market presence.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Introduction
The Disease Burden
Immunotherapy also Immuno oncology
Monoclonal antibodies OR Mabs
Adoptive cell transfer (ACT)
Cytokines
Therapeutic Cancer Vaccines
Immunotherapy Landscape
Emerging Immunotherapy
CAR T
Cost of Immuno oncology
Regulation
Astra Zeneca Oncology Pipeline
Bristol Meyers Squibb Oncology Pipeline
Competitive Landscape
Novartis
Pfizer
Company Profiles
Bristol Myer Squib
Merck & Co
Astra Zeneca
Roche
The Three C’s of the Oncology Market
Research Methodology
Secondary Research
Primary Research
Models -48
Forecasts
Rcubes Market Research & Consulting
About Us
Contact Us
Disclaimer -49
The Disease Burden
Immunotherapy also Immuno oncology
Monoclonal antibodies OR Mabs
Adoptive cell transfer (ACT)
Cytokines
Therapeutic Cancer Vaccines
Immunotherapy Landscape
Emerging Immunotherapy
CAR T
Cost of Immuno oncology
Regulation
Astra Zeneca Oncology Pipeline
Bristol Meyers Squibb Oncology Pipeline
Competitive Landscape
Novartis
Pfizer
Company Profiles
Bristol Myer Squib
Merck & Co
Astra Zeneca
Roche
The Three C’s of the Oncology Market
Research Methodology
Secondary Research
Primary Research
Models -48
Forecasts
Rcubes Market Research & Consulting
About Us
Contact Us
Disclaimer -49
LIST OF TABLES
Table 1: Global Prevalence of Cancer, 2012 (In 000s)
Table 2: Leading causes of death in US, 2014
Table 3: Common Causes of Cancer Death, 2012
Table 4: Estimated New Cancer Cases and Deaths in US, By Cancer Type, 2016
Table 5: Cancer Survival Rates
Table 6: Global Market for Oncology Therapy Market (2015)
Table 7: The Future Product Lines Of Oncology Companies
Table 8: Global Oncology Market, By Region
Table 9: Top Oncology Drugs and Their Indications
Table 10: Global Top 10 Selling Oncology Drugs in 2013 & 2015
Table 11: Company Overview
Table 12: Key Brands and Revenues
Table 13: Geographical Split
Table 14: Key Oncology Brands ($M)
Table 15: Company Overview -34
Table 16: Key Brands and Revenues
Table 17: Geography Split
Table 18: Oncology Brands
Table 19: Company Overview
Table 20: Geographical Split
Table 21: Oncology Brands
Table 22: Company Overview
Table 23: Key Brands and Revenues, 2015
Table 24: Geographical Split (2015) -39
Table 25: Oncology Brands (2014-16)
Table 26: Top Oncology Companies (2014-2020)
Table 27: Top Oncology Drugs By Revenues in 2020
Table 1: Global Prevalence of Cancer, 2012 (In 000s)
Table 2: Leading causes of death in US, 2014
Table 3: Common Causes of Cancer Death, 2012
Table 4: Estimated New Cancer Cases and Deaths in US, By Cancer Type, 2016
Table 5: Cancer Survival Rates
Table 6: Global Market for Oncology Therapy Market (2015)
Table 7: The Future Product Lines Of Oncology Companies
Table 8: Global Oncology Market, By Region
Table 9: Top Oncology Drugs and Their Indications
Table 10: Global Top 10 Selling Oncology Drugs in 2013 & 2015
Table 11: Company Overview
Table 12: Key Brands and Revenues
Table 13: Geographical Split
Table 14: Key Oncology Brands ($M)
Table 15: Company Overview -34
Table 16: Key Brands and Revenues
Table 17: Geography Split
Table 18: Oncology Brands
Table 19: Company Overview
Table 20: Geographical Split
Table 21: Oncology Brands
Table 22: Company Overview
Table 23: Key Brands and Revenues, 2015
Table 24: Geographical Split (2015) -39
Table 25: Oncology Brands (2014-16)
Table 26: Top Oncology Companies (2014-2020)
Table 27: Top Oncology Drugs By Revenues in 2020
LIST OF FIGURES
Figure 1: Cancer Survival Rates
Figure 2: Immunotherapy
Figure 3: Global Oncology Therapy Market, 2015
Figure 4: Future of Oncology – Combination Therapies
Figure 5: Astra Zeneca Oncology Pipeline
Figure 6: Bristol Meyers Squibb Oncology Pipeline
Figure 7: Roche Oncology Pipeline
Figure 8: Top Ten Oncology Companies
Figure 9: Top 15 Oncology Drugs, 2020
Figure 1: Cancer Survival Rates
Figure 2: Immunotherapy
Figure 3: Global Oncology Therapy Market, 2015
Figure 4: Future of Oncology – Combination Therapies
Figure 5: Astra Zeneca Oncology Pipeline
Figure 6: Bristol Meyers Squibb Oncology Pipeline
Figure 7: Roche Oncology Pipeline
Figure 8: Top Ten Oncology Companies
Figure 9: Top 15 Oncology Drugs, 2020
